一分钟看懂
这是一项关于子宫内膜癌的III 期研究，登记的药物或干预包括Pembrolizumab；Carboplatin；Paclitaxel；Docetaxel；Sacituzumab Tirumotecan；Cisplatin，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab；Carboplatin；Paclitaxel；Docetaxel；Sacituzumab Tirumotecan；Cisplatin · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Hospital ( Site 0830) · 合肥
- Peking University Peoples Hospital ( Site 0845) · 北京
- Chongqing University Cancer Hospital ( Site 0838) · 重庆
- Fujian Province Cancer Hospital ( Site 0802) · 福州
- The First Affiliated hospital of Xiamen University ( Site 0822) · 厦门
- Sun Yat-sen University Cancer Center ( Site 0846) · 广州
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 0801) · 广州
- Zhujiang Hospital of Southern Medical University ( Site 0829) · 广州
- Cancer Hospital of Shantou University Medical College ( Site 0827) · 汕头
- Affiliated Hospital of Guangdong Medical University ( Site 0823) · 湛江
- Liuzhou People's Hospital ( Site 0831) · 柳州
- Guangxi Medical University Affiliated Tumor Hospital. ( Site 0825) · 南宁
- Harbin Medical University Cancer Hospital ( Site 0850) · 哈尔滨
- Henan Cancer Hospital ( Site 0806) · 郑州
- The Second Affiliated Hospital of Zhengzhou University ( Site 0833) · 郑州
- Wuhan Union Hospital Cancer Center ( Site 0824) · 武汉
- Xiangya Hospital Central South University ( Site 0821) · 长沙
- Hunan Cancer Hospital ( Site 0826) · 长沙
- Nanjing First Hospital ( Site 0828) · 南京
- Jiangxi Maternal and Child Health Hospital ( Site 0807) · 南昌
- The First Hospital Of Jilin University ( Site 0815) · 长春
- The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0816) · 西安
- Shandong Cancer Hospital ( Site 0803) · 济南
- LinYi Cancer Hospital ( Site 0820) · 临沂
- Shanghai Tenth People's Hospital ( Site 0847) · 上海
- Obstetrics & Gynecology Hospital of Fudan University ( Site 0818) · 上海
- Shanxi Provincial Cancer Hospital ( Site 0843) · 太原
- West China Second University Hospital, Sichuan University ( Site 0849) · 成都
- The Second People's Hospital of Yibin ( Site 0840) · 宜宾
- Yunnan Province Cancer Hospital ( Site 0811) · 昆明
- The Affiliated Women's Hospital of Zhejiang University ( Site 0834) · 杭州
- Taizhou Hospital of Zhejiang Province ( Site 0809) · 临海
- The First Affiliated Hospital of Wenzhou Medical University ( Site 0805) · 温州
公开的入选条件
- Key inclusion criteria include but are not limited to:
- * Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR)
- * Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator
- * Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radia
- Key exclusion criteria include but are not limited to:
- * Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas
- * Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR)
- * Is a candidate for debulking surgery resulting in complete removal of all tumor and no evidence of radiological disease following surgery, or curative-intent radiotherapy at the time of enrollment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06952504；登记信息更新于 2026-09-17。